Logo image of FOLD

AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis

USA - NASDAQ:FOLD - US03152W1099 - Common Stock

8.33 USD
-0.15 (-1.77%)
Last: 9/19/2025, 8:00:00 PM
8.44 USD
+0.11 (+1.32%)
After Hours: 9/19/2025, 8:00:00 PM
Fundamental Rating

4

Overall FOLD gets a fundamental rating of 4 out of 10. We evaluated FOLD against 540 industry peers in the Biotechnology industry. While FOLD is still in line with the averages on profitability rating, there are concerns on its financial health. FOLD has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year FOLD has reported negative net income.
In the past year FOLD has reported a negative cash flow from operations.
In the past 5 years FOLD always reported negative net income.
FOLD had a negative operating cash flow in each of the past 5 years.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

FOLD's Return On Assets of -4.67% is amongst the best of the industry. FOLD outperforms 87.22% of its industry peers.
With an excellent Return On Equity value of -18.65%, FOLD belongs to the best of the industry, outperforming 85.93% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.06%, FOLD belongs to the top of the industry, outperforming 90.93% of the companies in the same industry.
Industry RankSector Rank
ROA -4.67%
ROE -18.65%
ROIC 3.06%
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With an excellent Operating Margin value of 4.39%, FOLD belongs to the best of the industry, outperforming 90.37% of the companies in the same industry.
Looking at the Gross Margin, with a value of 90.37%, FOLD belongs to the top of the industry, outperforming 91.85% of the companies in the same industry.
FOLD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.39%
PM (TTM) N/A
GM 90.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
FOLD has a better debt/assets ratio than last year.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.87, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
FOLD has a Altman-Z score (-0.87) which is in line with its industry peers.
A Debt/Equity ratio of 1.92 is on the high side and indicates that FOLD has dependencies on debt financing.
The Debt to Equity ratio of FOLD (1.92) is worse than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.92
Debt/FCF N/A
Altman-Z -0.87
ROIC/WACC0.29
WACC10.5%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

FOLD has a Current Ratio of 3.21. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD has a worse Current ratio (3.21) than 61.67% of its industry peers.
FOLD has a Quick Ratio of 2.29. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.29, FOLD is doing worse than 69.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.21
Quick Ratio 2.29
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.79% over the past year.
Looking at the last year, FOLD shows a very strong growth in Revenue. The Revenue has grown by 25.35%.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)71.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)25.35%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%22.12%

3.2 Future

The Earnings Per Share is expected to grow by 70.90% on average over the next years. This is a very strong growth
FOLD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.28% yearly.
EPS Next Y67.89%
EPS Next 2Y89.72%
EPS Next 3Y73.76%
EPS Next 5Y70.9%
Revenue Next Year18.91%
Revenue Next 2Y19.82%
Revenue Next 3Y19.71%
Revenue Next 5Y19.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 28.94.
FOLD's Price/Forward Earnings ratio is rather cheap when compared to the industry. FOLD is cheaper than 90.93% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.86, FOLD is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 28.94
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, FOLD is valued cheaply inside the industry as 89.81% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 82
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 73.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.72%
EPS Next 3Y73.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FOLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (9/19/2025, 8:00:00 PM)

After market: 8.44 +0.11 (+1.32%)

8.33

-0.15 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners95.61%
Inst Owner Change1.1%
Ins Owners0.6%
Ins Owner Change2.43%
Market Cap2.57B
Analysts83.33
Price Target16.22 (94.72%)
Short Float %7.49%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.84%
Min EPS beat(2)-26.06%
Max EPS beat(2)41.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.25%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)7
Avg Revenue beat(12)-0.51%
Revenue beat(16)8
Avg Revenue beat(16)-1.25%
PT rev (1m)0%
PT rev (3m)1.49%
EPS NQ rev (1m)15.38%
EPS NQ rev (3m)53.44%
EPS NY rev (1m)35.44%
EPS NY rev (3m)23.87%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)0.85%
Revenue NY rev (3m)0.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 28.94
P/S 4.5
P/FCF N/A
P/OCF N/A
P/B 12.57
P/tB N/A
EV/EBITDA 82
EPS(TTM)-0.11
EYN/A
EPS(NY)0.29
Fwd EY3.46%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.85
BVpS0.66
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.67%
ROE -18.65%
ROCE 3.87%
ROIC 3.06%
ROICexc 4.75%
ROICexgc 9.73%
OM 4.39%
PM (TTM) N/A
GM 90.37%
FCFM N/A
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 1.92
Debt/FCF N/A
Debt/EBITDA 11.88
Cap/Depr 41.25%
Cap/Sales 0.57%
Interest Coverage 0.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.21
Quick Ratio 2.29
Altman-Z -0.87
F-Score5
WACC10.5%
ROIC/WACC0.29
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y67.89%
EPS Next 2Y89.72%
EPS Next 3Y73.76%
EPS Next 5Y70.9%
Revenue 1Y (TTM)25.35%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%22.12%
Revenue Next Year18.91%
Revenue Next 2Y19.82%
Revenue Next 3Y19.71%
Revenue Next 5Y19.28%
EBIT growth 1Y191.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.62%
EBIT Next 3Y105.52%
EBIT Next 5YN/A
FCF growth 1Y63.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.94%
OCF growth 3YN/A
OCF growth 5YN/A